UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K/A
(Amendment No. 1)
(Mark one)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-36020
Onconova Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
375 Pheasant Run, Newtown, PA
(Address of principal executive offices)
22-3627252
(I.R.S. Employer
Identification No.)
18940
(Zip Code)
(267) 759-3680
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, par value $.01 per share
Common Stock Warrants
Trading Symbol(s)
ONTX
ONTXW
Name of each exchange on which registered
The Nasdaq Stock Market LLC
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S- T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,
or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”, “smaller reporting company,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. Yes ☐ No ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act). Yes ☐ No ☒
As of June 30, 2020, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the
registrant’s voting stock held by non-affiliates was approximately $98.4 million, based on the last reported sale price of the registrant’s common stock on
the Nasdaq Capital Market.
There were 236,612,391 shares of common stock outstanding as of March 1, 2021.
ONCONOVA THERAPEUTICS, INC.
FORM 10-K/A
For Fiscal Year Ended December 31, 2020
TABLE OF CONTENTS
Item 10
Item 11
Item 12
Item 13
Item 14
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accountant Fees and Services
PART III
Item 15
Exhibits and Financial Statement Schedules
PART IV
i
Page
1
7
13
15
15
16
EXPLANATORY NOTE
Onconova Therapeutics, Inc., sometimes referred to as “we,” “our,” or the “Company” is filing this Amendment No. 1 on Form 10-K/A, or this
Amendment, to its Annual Report on Form 10-K for the year ended December 31, 2020, originally filed on March 18, 2021, or the “Original Report,” for
the sole purpose of including the information required by Part III of Form 10-K. This information was previously omitted from the Original Report in
reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by
reference from our definitive proxy statement if such statement is filed no later than 120 days after the our fiscal year-end. We are filing this Amendment to
provide information required in Part III of Form 10-K because a definitive proxy statement containing such information will not be filed by the Company
within 120 days after the end of the fiscal year covered by the Form 10-K.
In accordance with Rule 12b-15 under the Securities and Exchange Act of 1934, as amended, or the Exchange Act, Part III, Items 10 through 14 of the
Original Report are hereby amended and restated in their entirety, and Part IV, Item 15 of the Original Report is hereby amended and restated in its entirety,
with the only changes being the addition of the new certifications by our principal executive officer and principal financial officer filed herewith. This
Amendment does not amend or otherwise update any other information in the Original Report. Accordingly, this Amendment should be read in conjunction
with the Original Report and with our filings with the Securities and Exchange Commission subsequent to the Original Report.
ii
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
PART III
All of our directors bring to our Board of Directors executive leadership experience from their service as executives and/or directors of our Company
and/or other entities. The biography of each of the nominees below contains information regarding the person's business experience, director positions held
currently or at any time during the last five years, and the experiences, qualifications, attributes and skills that caused the Nominating and Corporate
Governance Committee and our Board of Directors to determine that the person should serve as a director, given our business and structure.
Name
Jack E. Stover
James J. Marino
Jerome E. Groopman, M.D.
Steven M. Fruchtman
M. Teresa Shoemaker
Viren Mehta
Age
68
71
69
70
60
71
Position(s) with Onconova Therapeutics, Inc.
Director
Chairman of the Board of Directors
Director
Director, President and Chief Executive Officer
Director
Director
Served as
Director
From
2016
2015
2013
2019
2020
2004
Jack E. Stover. Mr. Stover has served as a member of our Board of Directors since May 2016. Since March 2021, Mr. Stover has been Chief
Executive Officer of NorthView Acquisition Corp. From December 2015 until June 2016, Mr. Stover served as Interim President and CEO of Interpace
Diagnostics Group, Inc. (“Interpace”) and, since August 2005, served on the Board of Directors of Interpace and was chairman of Interpace’s audit
committee from August 2005 until December 2015. In June 2016 until December 2020, Mr. Stover was President, CEO and Director of Interpace, which in
2019 changed its name to Interpace Biosciences, Inc. From June 2016 to December 2016, Mr. Stover was chairman of the audit committee and a member
of the Board of Directors of Viatar CTC Solutions, Inc. From 2004 to 2008, he served as Chief Executive Officer, President and Director of Antares
Pharma, Inc., a publicly held specialty pharmaceutical company then listed on the American Stock Exchange and subsequently Nasdaq. In addition to other
relevant experience, Mr. Stover was also formerly a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience industry
division in New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.
Our Board of Directors believes that Mr. Stover's experience holding senior leadership positions in the life sciences industry, his specific experience
and skills in the areas of general operations, and financial operations and administration, and his extensive experience in accounting and as an
audit committee member and chair of various public companies in the life sciences industry, provide him with the qualifications and skills to serve as a
director.
James J. Marino. Mr. Marino has served as Chairman of the Board of Directors since August 2020 and as a member of our Board of Directors since
July 2015. Prior to July 2015, Mr. Marino was a Partner at the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the
Princeton Office. Mr. Marino served as the outside counsel for the Company from its inception through and including its initial public offering. On
March 8, 2017, Mr. Marino was appointed to the Board of Directors and as chairperson of the compensation committee of Celldex Therapeutics, Inc., a
public company which is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Previously, he
served on the Board of Directors of Pharmacopeia Drug Discovery, Inc. from 2000 to 2006 and has worked in advisory capacities and on the boards of
multiple non-profit organizations. He recently served on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical
Center. Mr. Marino received his B.A., J.D. and MBA from Rutgers University.
Our Board of Directors believes that Mr. Marino's perspective and experience advising the Company and numerous other leading life science
companies in connection with financings, acquisitions and strategic alliances, provide him with the qualifications and skills to serve as a director.
Jerome E. Groopman, M.D. Dr. Groopman has served as a member of our Board of Directors since July 2013. Dr. Groopman has served as the Dina
and Raphael Recanati Professor of Medicine at Harvard Medical School since January 1992. He has also served as Attending Hematologist/Oncologist at
Beth Israel Deaconess Medical Center since July 1996. Dr. Groopman received an M.D. from Columbia University College of Physicians and Surgeons,
and a B.A. in Political Philosophy from Columbia College.
Our Board of Directors believes Dr. Groopman's perspective and experience in the healthcare industry, as well as his educational background, provide
him with the qualifications and skills to serve as a director.
Steven M. Fruchtman, M.D. Dr. Fruchtman was appointed as a member of our Board of Directors and as our Chief Executive Officer on January 15,
2019. He was appointed President in June 2018 and continues to serve as President. Dr. Fruchtman served as our Chief Medical Officer and Senior Vice
President, Research and Development from January 2015 to November 2018. Dr. Fruchtman is a board certified hematologist with extensive industry
experience in clinical research for myelodysplastic syndromes, hematologic malignancies and solid tumors.
From June 2014 to January 2015, Dr. Fruchtman was a hematology oncology drug development consultant. From September 2013 to June 2014,
Dr. Fruchtman served as Chief Medical Officer at Syndax Pharmaceuticals, Inc., a biopharmaceutical company. From July 2011 to July 2013,
Dr. Fruchtman was the Chief Medical Officer and Senior Vice President of Research and Regulatory Affairs at Spectrum Pharmaceuticals, a
biopharmaceutical company (“Spectrum”). From February 2011 to June 2011, he was Vice President of Research at Spectrum. From February 2009 to
January 2011, Dr. Fruchtman was Vice President, Clinical Research at Allos Therapeutics, Inc., a biopharmaceutical company. Prior to this, Dr. Fruchtman
held senior positions at Novartis and Ortho Biotech Products. Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and was the
Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. Dr. Fruchtman received his
medical degree from New York Medical College and his B.A. from Cornell University.
Our Board of Directors believes Dr. Fruchtman's perspective and experience as our Chief Medical Officer, President and Chief Executive Officer, as
well as his depth of experience in the healthcare industry and his educational background, provide him with the qualifications and skills to serve as a
director.
M. Teresa Shoemaker. Ms. Shoemaker has served as a member of our Board of Directors since April 2020. Ms. Shoemaker served as the President
and CEO of Medexus Pharmaceuticals, Inc. (“Medexus”) from October 2018 to May 2020. Prior to joining Medexus, she served as President and CEO and
board member of Medac Pharma, Inc. from its inception in June 2012 until its acquisition by Medexus in October 2018. Ms. Shoemaker implemented
Medac's commercial strategy in support of a commercial product for the treatment of rheumatoid arthritis. Previously, Ms. Shoemaker served as Principal
and Co-Founder of BioPharm Strategic Solutions from 2010 to 2012. From October 2009 to July 2010, she served as Vice President of Sales at
InterMune, Inc. From 2002 to 2008, Ms. Shoemaker served as National Sales Director and then Sr. Director US Commercial Operations for Pharmion
Corporation (“Pharmion”). In 2008, when Celgene Corporation acquired Pharmion, Ms. Shoemaker remained as Executive Director of Strategic
Commercial Operations working as part of the executive transition team until 2009. Ms. Shoemaker began her career at DuPont Pharmaceuticals, which
was acquired by Bristol Myers Squibb in 2000, where she held a number of sales and marketing leadership positions. Ms. Shoemaker holds B.S. degrees in
Communication Science and Psychology from Missouri State University, and a M.S. degree in Communication Science and Disorders from University of
Central Missouri.
Our Board of Directors believes that Ms. Shoemaker's experience holding senior leadership positions in the life sciences industry and her specific
skills, developing and managing commercial organizations in the life sciences industry, provide her with the qualifications and skills to serve as a director.
Viren Mehta. Dr. Mehta has served as a member of our Board of Directors since February 2004. Dr. Mehta has been a managing member of Mehta
Partners since 1997. Mehta Partners provides strategic advisory services to the biotechnology and pharmaceutical companies worldwide. Prior to founding
Mehta Partners, Dr. Mehta co-founded Mehta and Isaly in 1989, and prior to that was a part of the strategic planning team of the International Division at
Merck & Co. Dr. Mehta earned a Doctor of Pharmacy at the University of Southern California, and an M.B.A. from the Anderson School of Business at the
University of California, Los Angeles. His board affiliations include BlinkBio, Yisheng Biopharma, Project Hope and the Venice Family Clinic.
Our Board of Directors believes Dr. Mehta's perspective and experience in the life sciences industry as a biopharma fund manager, fund consultant and
a strategic advisor to senior managers in the biopharma industry, as well as his educational background, provide him with the qualifications and skills to
serve as a director.
Executive Officers
The following table sets forth certain information regarding our executive officers who are not also directors.
Name
Abraham N. Oler, J.D.
Mark P. Guerin
Age
45
52
Position(s) with Onconova Therapeutics, Inc.
Senior Vice President, Corporate Development and General Counsel
Chief Financial Officer
Abraham N. Oler, J.D. Mr. Oler has served as our Senior Vice President, Corporate Development and General Counsel since January 2020.
Previously, he served as Vice President, Corporate Development and General Counsel since December 2018. Prior to joining us, from 2010 to 2018,
Mr. Oler was Vice President of Operations at Spectrum, where he headed the legal function and worked in corporate development. Additionally, he served
as Chief of Staff to the CEO and corporate secretary. He was also an officer and director for several Spectrum subsidiary companies. From 2007 to 2010,
Mr. Oler was a corporate attorney at the international law firm of Kirkland & Ellis LLP. Mr. Oler received his J.D. and an M.B.A. from Northwestern
University. He received an M.Sc. in Politics of the World Economy from the London School of Economics and a B.S.in Economics and a B.A. in
International Relations from the University of Pennsylvania.
Mark P. Guerin. Mr. Guerin has served as our Chief Financial Officer since September 1, 2016. Previously, he served as Vice President—Financial
Planning & Accounting, and Chief Accounting Officer since May 2014, and as Vice President—Financial Planning & Accounting from September 2013 to
May 2014. He has also served as our principal financial officer since February 12, 2016. Between January 2012 and September 2013, Mr. Guerin was self-
employed as a financial and accounting consultant. For more than six years, through December 2011, Mr. Guerin was employed by CardioKine, Inc. and
served as Chief Financial Officer from mid-2009 through December 2011. Mr. Guerin received his B.A. in Accounting from DeSales University.
2
Corporate Governance
Board Composition
Our Board of Directors currently consists of six members. Our Board of Directors has undertaken a review of the independence of our directors and
has determined that all directors, except Steven M. Fruchtman, M.D., are independent within the meaning of Section 5605(a)(2) of the NASDAQ Stock
Market listing rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our Tenth Amended and Restated
Certificate of Incorporation, as amended, provides that our Board of Directors will consist of not less than three nor more than 11 directors, as such number
of directors may from time to time be fixed by our Board of Directors. Each director shall be elected to the Board of Directors to hold office until the next
annual meeting of stockholders and until his or her successor is elected and qualified.
Board Leadership Structure and Role in Risk Oversight
Our Board of Directors recognizes the time, effort and energy that the chief executive officer is required to devote to his position in the current
business environment, as well as the commitment required to serve as our chairman, particularly as the Board of Directors' oversight responsibilities
continue to grow. We believe that, at present, separating these positions allows our chief executive officer to focus on our day-to-day business, while
allowing our chairman to lead the Board of Directors in its fundamental role of providing advice to, and independent oversight of, management. Our Board
of Directors also believes that this structure ensures a greater role for the independent directors in the oversight of our company and active participation of
the independent directors in setting agendas and establishing priorities and procedures for the work of our Board of Directors.
While our bylaws do not require that our chairman and chief executive officer positions be separate, our Board of Directors believes that having
separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.
Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including
but not limited to risks relating to limited cash resources, need to raise additional funds, product candidate development, technological uncertainty,
dependence on collaborative partners and other third parties, uncertainty regarding patents and proprietary rights, comprehensive government regulations,
having no commercial manufacturing experience, marketing or sales capability or experience and dependence on key personnel. Management is
responsible for the day-to-day management of risks we face, while our Board of Directors, as a whole and through its committees, has responsibility for the
oversight of risk management. In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management processes
designed and implemented by management are adequate and functioning as designed. The Board of Directors periodically consults with management
regarding the Company's risks.
Our Board of Directors is actively involved in oversight of risks that could affect us. This oversight is conducted primarily through the audit committee
of our Board of Directors, but the full Board of Directors has retained responsibility for general oversight of risks.
Board Committees
Our Board of Directors has established three standing committees: the audit committee, the compensation committee and the nominating and corporate
governance committee. The current members of our audit committee are James J. Marino, Viren Mehta and Jack E. Stover, with Jack E. Stover serving as
chairperson. The current members of our compensation committee are M. Teresa Shoemaker, James J. Marino and Jack E. Stover with M. Teresa
Shoemaker serving as chairperson. The current members of our nominating and corporate governance committee are M. Teresa Shoemaker, Viren Mehta
and Jerome E. Groopman, M.D., with Viren Mehta serving as chairperson.
Our Board of Directors has determined that James J. Marino, Viren Mehta and Jack E. Stover meet the additional test for independence for audit
committee members imposed by Securities and Exchange Commission ("SEC") regulations and Section 5605(c)(2)(A) of the NASDAQ Stock Market
listing rules and that M. Teresa Shoemaker, James J. Marino and Jack E. Stover meet the additional test for independence for compensation
committee members imposed by Section 5605(d)(2)(A) of the NASDAQ Stock Market listing rules.
Audit Committee
The primary purpose of our audit committee is to assist the Board of Directors in the oversight of the integrity of our accounting and financial
reporting process, the audits of our consolidated financial statements, and our compliance with legal and regulatory requirements. Our audit committee met
four times during fiscal year 2020. The functions of our audit committee include, among other things:
• hiring the independent registered public accounting firm to conduct the annual audit of our consolidated financial statements and monitoring its
independence and performance;
• reviewing and approving the planned scope of the annual audit and the results of the annual audit;
3
• pre-approving all audit services and permissible non-audit services provided by our independent registered public accounting firm;
• reviewing the significant accounting and reporting principles to understand their impact on our consolidated financial statements;
• reviewing our internal financial, operating and accounting controls with management, our independent registered public accounting firm and our
internal audit provider;
• reviewing with management and our independent registered public accounting firm, as appropriate, our financial reports, earnings
announcements and our compliance with legal and regulatory requirements;
• periodically reviewing and discussing with management the effectiveness and adequacy of our system of internal controls;
• in consultation with management and the independent auditors, reviewing the integrity of our financial reporting process and adequacy of
disclosure controls;
• reviewing potential conflicts of interest under and violations of our code of conduct;
• establishing procedures for the treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters and
confidential submissions by our employees of concerns regarding questionable accounting or auditing matters;
• reviewing and approving related-party transactions; and
• reviewing and evaluating, at least annually, our audit committee's charter.
With respect to reviewing and approving related-party transactions, our audit committee reviews related-party transactions for potential conflicts of
interests or other improprieties. Under SEC rules, as a smaller reporting company, related-party transactions are those transactions to which we are or may
be a party in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal
years, and in which any of our directors or executive officers or any other related person had or will have a direct or indirect material interest, excluding,
among other things, compensation arrangements with respect to employment and Board of Directors membership. Our audit committee could approve a
related-party transaction if it determines that the transaction is in our best interests. Our directors are required to disclose to this committee or the full Board
of Directors any potential conflict of interest, or personal interest in a transaction that our Board of Directors is considering. Our executive officers are
required to disclose any related-party transaction to the audit committee. We also poll our directors on an annual basis with respect to related-party
transactions and their service as an officer or director of other entities. Any director involved in a related-party transaction that is being reviewed or
approved must recuse himself or herself from participation in any related deliberation or decision. Whenever possible, the transaction should be approved
in advance and if not approved in advance, must be submitted for ratification as promptly as practical.
The financial literacy requirements of the SEC require that each member of our audit committee be able to read and understand fundamental financial
statements. In addition, at least one member of our audit committee must qualify as an audit committee financial expert, as defined in Item 407(d)(5) of
Regulation S-K promulgated under the Securities Act, and have financial sophistication in accordance with the NASDAQ Stock Market listing rules. Our
Board of Directors has determined that Jack E. Stover qualifies as an audit committee financial expert.
Both our independent registered public accounting firm and management periodically will meet privately with our audit committee.
The Board of Directors has adopted a charter for the audit committee, which is available in the corporate governance section of our website at
http://www.onconova.com.
Compensation Committee
The primary purpose of our compensation committee is to assist our Board of Directors in exercising its responsibilities relating to compensation of
our executive officers and employees and to administer our equity compensation and other benefit plans. In carrying out these responsibilities, this
committee reviews all components of executive officer and employee compensation for consistency with its compensation philosophy, as in effect from
time to time. Our compensation committee met ten times during fiscal 2020. The functions of our compensation committee include, among other things:
• designing and implementing competitive compensation, retention and severance policies to attract and retain key personnel;
• reviewing and formulating policy and determining the compensation of our Chief Executive Officer, our other executive officers and employees;
• reviewing and recommending to our Board of Directors the compensation of our non-employee directors;
4
• reviewing and evaluating our compensation risk policies and procedures;
• administering our equity incentive plans and granting equity awards to our employees, consultants and directors under these plans;
• administering our performance bonus plans and granting bonus opportunities to our employees, consultants and non-employee directors under
these plans;
• if required from time to time, preparing the analysis or reports on executive officer compensation required to be included in our annual proxy
statement;
• engaging compensation consultants or other advisors it deems appropriate to assist with its duties; and
• reviewing and evaluating, at least annually, our compensation committee's charter.
The Board of Directors has adopted a charter for the compensation committee, which is available in the corporate governance section of our website at
http://www.onconova.com.
The compensation committee has utilized Radford ("Radford"), an Aon Hewitt company, as its executive compensation consultant. Radford reports
directly to the compensation committee. The compensation committee may replace Radford or hire additional consultants at any time. Upon request by the
compensation committee or its chair, a representative of Radford attends meetings of the compensation committee and is available to discuss compensation
issues in between meetings.
In connection with its work for the compensation committee, Radford provided various executive compensation services to the compensation
committee pursuant to a written consulting agreement. Generally, these services included advising the compensation committee on the principal aspects of
our executive compensation program and evolving industry practices and providing market information and analysis regarding the competitiveness of our
program design and our award values in relation to performance.
The compensation committee retains sole authority to hire any compensation consultant, approve such consultant's compensation, determine the nature
and scope of its services, evaluate its performance, and terminate its engagement. We assessed the independence of Radford pursuant to SEC rules and
determined that no known conflict of interest existed that would prevent Radford from serving as an independent consultant to the compensation
committee.
The compensation committee has reviewed our compensation policies and practices for all employees, including our named executive officers, as they
relate to risk management practices and risk-taking incentives, and has determined that there are no risks arising from these policies and practices that are
reasonably likely to have a material adverse effect on us.
Nominating and Corporate Governance Committee
The primary purpose of our nominating and corporate governance committee is to assist our Board of Directors in promoting the best interest of our
company and our stockholders through the implementation of sound corporate governance principles and practices. Our nominating and corporate
governance committee met four times during fiscal 2020. The functions of our nominating and corporate governance committee include, among other
things:
• identifying, reviewing and evaluating candidates to serve on our Board of Directors;
• determining the minimum qualifications for service on our Board of Directors;
• developing and recommending to our Board of Directors an annual self-evaluation process for our Board of Directors and overseeing the annual
self-evaluation process;
• developing, as appropriate, a set of corporate governance principles, and reviewing and recommending to our Board of Directors any changes to
such principles; and
• periodically reviewing and evaluating our nominating and corporate governance committee's charter.
The Board of Directors has adopted a charter for the nominating and corporate governance committee, which is available in the corporate governance
section of our website at http://www.onconova.com.
Code of Conduct for Employees, Executive Officers and Directors
We have adopted a code of conduct applicable to all of our employees, executive officers and directors. The code of conduct is available in the
corporate governance section of our website at http://www.onconova.com.
5
The audit committee of our Board of Directors is responsible for overseeing the code of conduct and must approve any waivers of the code of conduct
for employees, executive officers or directors.
Meetings of the Board of Directors
The Board of Directors held eleven meetings during fiscal 2020. During fiscal 2020, each director attended at least 75 percent of the aggregate of the
total number of meetings of the Board of Directors and the committees on which such director served.
Directors are encouraged, but not required, to attend the annual meeting of stockholders. All of our directors attended the 2020 Annual Meeting of
Stockholders.
Director Nomination Process
The process followed by our nominating and corporate governance committee to identify and evaluate director candidates includes requests to
members of our Board of Directors and others for recommendations, meetings from time to time to evaluate biographical information and background
material relating to potential candidates and interviews of selected candidates by members of the nominating and corporate governance committee and the
Board of Directors.
In determining whether to recommend any particular candidate for inclusion in the Board of Directors' slate of recommended director nominees, our
nominating and corporate governance committee considers the composition of the Board of Directors with respect to depth of experience, balance of
professional interests, required expertise and other factors. The nominating and corporate governance committee considers the value of diversity when
recommending candidates. The committee views diversity broadly to include diversity of experience, skills and viewpoint. The nominating and corporate
governance committee does not assign specific weights to particular criteria and no particular criterion is a prerequisite for each prospective nominee. Our
Board of Directors believe that the backgrounds and qualifications of its directors, considered as a group, should provide a composite mix of experience,
knowledge and abilities that will allow it to fulfill its responsibilities.
Stockholders may recommend individuals to our nominating and corporate governance committee for consideration as potential director candidates.
The nominating and corporate governance committee will evaluate stockholder-recommended candidates by following the same process and applying the
same criteria as it follows for candidates submitted by others.
Stockholders may directly nominate a person for election to our Board of Directors by complying with the procedures set forth in Section 2.2(A) of our
bylaws, and with the rules and regulations of the SEC. Under our bylaws, only persons nominated in accordance with the procedures set forth in the bylaws
will be eligible to serve as directors. In order to nominate a candidate for service as a director, you must be a stockholder at the time you give the Board of
Directors notice of your nomination, and you must be entitled to vote for the election of directors at the meeting at which your nominee will be considered.
In addition, the stockholder must have given timely notice in writing to our Secretary. To be timely, a stockholder's notice must be delivered to the
Secretary at our principal executive offices not later than the 90th day, nor earlier than the 120th day, prior to the first anniversary of the prior year's annual
meeting of stockholders (provided, however, that in the event that the date of the annual meeting is more than 30 days before or 60 days after such
anniversary date, notice by the stockholder must be delivered no earlier than the 120th day prior to the annual meeting and no later than the later of the
90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such annual meeting is first made by
us). Your notice must set forth (i) the name, age, business address and, if known, residence address of the nominee, (ii) the principal occupation or
employment of the nominee, (iii) the class and number of shares of stock of the Company directly or indirectly, owned beneficially or of record by the
nominee, (iv) a description of all arrangements or understandings between you and the nominee and any other person or persons (naming such person or
persons) pursuant to which the nomination is to be made by you, and (v) all other information relating to the nominee that is required to be disclosed in
solicitations of proxies for the election of directors in an election contest, or is otherwise required, in each case, pursuant to Section 14 of the Exchange Act
and the rules and regulations promulgated thereunder. Nominations for director must be accompanied by the nominee's written consent to being named in
the proxy statement as a nominee and to serving as a director if elected.
Stockholder Communications with the Board of Directors
You can contact our Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.
President
Onconova Therapeutics, Inc.
375 Pheasant Run
Newtown, PA 18940
United States
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a stockholder, customer, supplier,
or other interested party.
6
Communications are distributed to our Board of Directors, or to any individual directors, as appropriate, depending on the facts and circumstances
outlined in the communication.
ITEM 11. EXECUTIVE COMPENSATION.
Overview of Executive Compensation
The compensation committee of our Board of Directors is responsible for overseeing the compensation of all of our executive officers. In this capacity,
our compensation committee annually reviews and approves the compensation of our chief executive officer and other executive officers, including such
goals and objectives relevant to the executive officers' compensation that the committee, in its discretion, determines are appropriate, evaluates their
performance in light of those goals and objectives, and sets their compensation based on this evaluation.
2020 Summary Compensation Table
The following table sets forth information for the fiscal years ended December 31, 2020 and 2019 concerning compensation of our principal executive
officer and the two most highly compensated executive officers during 2020. We refer to these four executive officers as our "named executive officers."
Name and Principal Position
Steven M. Fruchtman, M.D.(5)
President and Chief Executive
Officer
Manoj Maniar, Ph.D.(6)
Senior Vice President, Product
Development
Richard C. Woodman, M.D.(7)
Chief Medical Officer and
Senior Vice President,
Research and Development
Mark Guerin
Chief Financial Officer
Year
2020
2019
2020
2019
2020
2019
2020
2019
$
$
$
$
Share-
Based
Awards
($)(2)
Bonus
($)(1)
Stock
Awards
($)(3)
All Other
Compensation
($)(4)
Total
($)
280,000 $
61,507 $
118,173 $
23,214 $
1,045,118
Salary
($)
562,224 $
509,215
451,500 $
191,452
109,402 $
50,000
20,212 $
--
38,822 $
21,846
558,555 $
772,513
1,178,491
416,795
393,750 $
133,580
99,750 $
10,750
19,121 $
--
36,733 $
14,933
2,171 $
576,058
551,525
375,000
374,816 $
353,600
18,740
108,909 $
108,800
20,000
26,219 $
16,250
--
50,364 $
--
11,572
28,467 $
26,458
425,312
588,775
505,108
(1) Represents discretionary annual bonus amounts paid.
(2) The amounts shown for 2020 represent the aggregate grant date fair value related to the grant of stock appreciation rights to our named executive
officers in fiscal 2020 calculated in accordance with FASB ASC Topic 718 (excluding the effect of any estimate of future forfeitures). The
amounts shown for 2019 represent the aggregate grant date fair value related to the grant of non-qualified stock options to our named executive
officers in fiscal 2019, calculated in accordance with FASB ASC Topic 718 (excluding the effect of any estimate of future forfeitures). Additional
information concerning our financial reporting of stock appreciation rights and stock options is presented in Note 10 to our Consolidated Financial
Statements set forth in our Annual Report on Form 10-K for the year ended December 31, 2020. See the “Outstanding Equity Awards at Fiscal
Year-End – 2020” table below for additional details regarding the stock appreciation rights that were granted to our named executive officers in
fiscal 2020.
(3) The amounts shown represent the aggregate grant date fair value related to the grant of performance stock units to our named executive officers in
fiscal 2020, calculated in accordance with FASB ASC Topic 718 (excluding the effect of any estimate of future forfeitures). Additional
information concerning our financial reporting of performance stock units is presented in Note 10 to our Consolidated Financial Statements set
forth in our Annual Report on Form 10-K for the year ended December 31, 2020. See the “Outstanding Equity Awards at Fiscal Year-End – 2020”
table below for additional details regarding the performance stock units that were granted to our named executive officers in fiscal 2020.
(4) Includes amounts paid for insurance premiums on behalf of the named executive officer and matching funds paid pursuant to our 401(k) Plan.
(5) Dr. Fruchtman was appointed as our Chief Executive Officer and a director on January 15, 2019.
(6) Dr. Maniar was terminated as our Senior Vice President, Product Development on December 15, 2020, which termination was treated as a
termination without cause. In connection with Dr. Maniar’s termination from employment, in accordance with the terms of his employment
agreement, dated dated July 1, 2015 and his stock appreciation rights agreement, he was due severance equal to nine months of his then current
base salary, plus target bonus ($519,225), reimbursement for COBRA for nine months (approximately $9,798 in value), and acceleration of his
outstanding stock options and stock appreciation rights (approximately $494 in value, based on spread as of his termination date). The total of
these termination expenses of $529,517 is included in the All Other Compensation column for Dr. Maniar for 2020.
(7) Dr. Woodman resigned as our Senior Vice President, Research and Development and Chief Medical Officer on January 15, 2021.
7
Employment Agreements
We have entered into employment agreements with each of our named executive officers, and the compensation of our named executive officers is
determined, in large part, by the terms of those employment agreements. Following are descriptions of the material terms of each named executive officer’s
employment agreement.
Steven Fruchtman, M.D.
We entered into an employment agreement with Dr. Fruchtman on June 19, 2018, which supersedes any prior employment agreements (the
“Employment Agreement”). The employment agreement continues indefinitely, unless terminated in accordance with the terms of the agreement. On
March 18, 2021, we entered into an amendment to the Original Agreement (the “Amendment”).
The Employment Agreement provides for an initial base salary of $510,000, subject to adjustment upon annual review, and subject to the
compensation committee's sole discretion, an annual bonus, based on the performance of Dr. Fruchtman and the Company, of up to 50% of such base
salary. The bonus may be paid in the form of cash, stock options, shares of our common stock, or a combination thereof, at our compensation committee's
discretion.
Dr. Fruchtman is entitled to participate in all of our employee benefit plans and programs that are made generally available from time to time to our
executive officers and is entitled to vacation benefits. Dr. Fruchtman's Employment Agreement contains non-solicitation, non-competition, confidentiality
and inventions assignment provisions that, among other things, prevent him from competing with us during the term of his employment and for a specified
time thereafter. The Company will reimburse Dr. Fruchtman for reasonable expenses including certain commuting costs to the Company's offices.
If Dr. Fruchtman's employment is terminated due to his death, disability, by us for "cause" or by Dr. Fruchtman without "good reason" during the term
of his employment agreement, we will pay to Dr. Fruchtman or his spouse or estate the balance of his accrued and unpaid salary, unreimbursed expenses,
and unused accrued vacation time through the termination date.
If Dr. Fruchtman's employment is terminated by us without "cause" or by Dr. Fruchtman for "good reason," other than during a change in control
protection period, Dr. Fruchtman will be entitled to receive severance equal to the sum of his current base salary and target bonus for the fiscal year during
which his employment ceases. If the termination is during a change in control protection period, Dr. Fruchtman will be entitled to receive severance equal
to the sum of his current base salary and target bonus for the fiscal year during which his employment ceases. A change in control protection period is the
twelve months following a change in control. The Company will also reimburse Dr. Fruchtman for a portion of his medical insurance costs and all of
Dr. Fruchtman's stock options that are unvested as of the date of such termination would fully vest as of the date of termination. Any severance payments or
benefits provided to Dr. Fruchtman are subject to execution by Dr. Fruchtman of a release of claims.
The Amendment removed Section 4(d) of the Employment Agreement, under which if Dr. Fruchtman would voluntarily resign from employment
within three months following the Company’s appointment of a new Chief Executive Officer (other than Dr. Fruchtman) and upon not less than 30 days’
notice, Dr. Fruchtman would be entitled to receive seven months of his current base salary, and any outstanding unvested options to purchase shares of
Company common stock would become fully vested as of the date of termination.
In addition, under the Amendment, if Dr. Fruchtman’s employment is terminated by the Company without “cause” or by Dr. Fruchtman for “good
reason,” other than during the 12-month period following a change in control of the Company, Dr. Fruchtman will be entitled to receive twelve months of
his current base salary and target bonus. If the termination is during the 12-month period following a change in control of the Company, Dr. Fruchtman will
be entitled to receive the sum of one and one-half times of (i) his current base salary and (ii) target bonus. The Company will also reimburse Dr. Fruchtman
for the employer’s portion of his medical insurance costs under COBRA for twelve months if Dr. Fruchtman’s termination occurs other than during the 12-
month period following a change in control of the Company or for 18 months if Dr. Fruchtman’s termination occurs during the 12 month-period following
a change in control of the Company. In addition, all of Dr. Fruchtman’s stock options that are unvested as of the date of such termination will fully vest as
of the date of termination. Under the Amendment, in order to receive the forgoing severance benefits, Dr. Fruchtman must sign a release and waiver of
claims and such release becomes effective and irrevocable within 60 days of Dr. Fruchtman’s cessation of employment and Dr. Fruchtman’s continued
compliance with the certain restrictive covenants in the Agreement. To the extent any of the above severance payments are subject to Section 409A of the
Internal Revenue Code of 1986, as amended (“Section 409A”) and Dr. Fruchtman is classified as a “specified employee,” as defined in Section 409A, any
such payments will not be paid during the six-month period immediately following such termination.
The Amendment also includes a provision on whistleblower protection and trade secrets.
Mark Guerin
We entered into an employment agreement with Mr. Guerin on July 1, 2015, which supersedes any prior employment agreements. The employment
agreement continues indefinitely, unless terminated in accordance with the terms of the agreement.
8
The employment agreement provides for an initial base salary of $243,165, subject to adjustment upon annual review by our board of directors, and
subject to the compensation committee’s sole discretion, an annual bonus, based on the performance of Mr. Guerin and the Company, of up to 25% of such
base salary. The bonus may be paid in the form of cash, stock options, shares of Common Stock, or a combination thereof, at our compensation
committee’s discretion.
Mr. Guerin is entitled to participate in all of our employee benefit plans and programs that are made generally available from time to time to our
executive officers and is entitled to vacation benefits. Mr. Guerin’s employment agreement contains non-solicitation, non-competition, confidentiality and
inventions assignment provisions that, among other things, prevent him from competing with us during the term of his employment and for a specified time
thereafter.
If Mr. Guerin’s employment is terminated due to his death, disability, by us for “cause” or by Mr. Guerin without “good reason” during the term of his
employment agreement, we will pay to Mr. Guerin or his spouse or estate the balance of his accrued and unpaid salary, unreimbursed expenses, and unused
accrued vacation time through the termination date.
If Mr. Guerin’s employment is terminated by us without “cause” or by Mr. Guerin for “good reason,” other than during a change in control protection
period, Mr. Guerin will be entitled to receive severance equal to nine-twelfths of the sum of his current base salary and target bonus for the fiscal year
during which his employment ceases. If the termination is during a change in control protection period, Mr. Guerin will be entitled to receive severance
equal to the sum of his current base salary and target bonus for the fiscal year during which his employment ceases. A change in control protection period is
the twelve months following a change in control. The Company will also reimburse Mr. Guerin for a portion of his medical insurance costs and all of
Mr. Guerin’s incentive stock options that are unvested as of the date of such termination would fully vest as of the date of termination.
Stock Option and Other Compensation Plans
We maintain the 2018 Plan for the purpose of attracting key employees, directors and consultants, inducing them to remain with us and encouraging
them to increase their efforts to make our business more successful. The plan provides for awards of stock options, stock appreciation rights, restricted
stock, restricted stock units, deferred shares and other equity-based awards.
The following table contains certain information regarding equity awards held by the named executive officers as of December 31, 2020:
9
Name
Steven Fruchtman
Manoj Maniar
Richard C. Woodman
Mark Guerin
Outstanding Equity Awards at 2020 Fiscal Year-End
Number of
Securities
Underlying
Unexercised
Options
(#) Exercisable
800(1)
233(1)
266(1)
827
1,666(2)
506(2)
1,760(2)
2,827(3)
21,478(4)
66,600(4)
1,273,800(6)
25
200
33
266
400
266(1)
266(1)
689
1,133(2)
372(2)
1,294(2)
1,907(3)
20,000(4)
5,000(5)
43,000(4)
418,600(6)
10,416(4)
26,640(4)
396,000(6)
200
40
163
166
100(1)
116(1)
312
999(2)
372(2)
1,294(2)
2,010(3)
20,670(4)
21,645(4)
543,000(6)
Number of
Securities
Underlying
Unexercised
Options
(#) Unexercisable
-
-
-
-
-
-
-
81
5,188
133,400
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
9,584
53,360
-
-
-
-
-
-
-
-
-
-
-
58
4,993
43,355
-
10
Option
Exercise Price
($)
Option
Expiration
Date
655.50
372.00
222.00
97.50
48.60
39.75
40.50
22.50
6.90
0.31
0.56
919.50
1,992.00
2,250.00
2,022.00
597.00
348.00
222.00
97.50
48.60
39.75
40.50
22.50
6.90
3.41
0.31
0.56
5.85
0.31
0.56
4,321.50
2,022.00
945.00
597.00
348.00
222.00
97.50
48.60
39.75
40.50
22.50
6.90
0.31
0.56
1/12/2025
4/20/2025
9/25/2025
1/26/2026
9/1/2026
12/15/2026
1/17/2027
1/3/2028
7/26/2028
12/20/2029
7/9/2030
12/5/2021
12/18/2022
7/25/2023
12/20/2023
12/18/2024
4/16/2025
9/25/2025
1/26/2026
9/1/2026
12/15/2026
1/17/2027
1/3/2028
7/26/2028
12/12/2028
12/20/2029
7/9/2030
11/5/2028
12/20/2029
7/9/2030
10/4/2023
12/20/2023
3/31/2024
12/18/2024
4/16/2025
9/25/2025
1/26/2026
9/1/2026
12/15/2026
1/17/2027
1/3/2028
7/26/2028
12/20/2029
7/9/2030
(1) 25% of the total shares underlying this option vested on July 25, 2014. The remaining shares vest 1/36th monthly over 36 months thereafter, subject
to continued service to us through each vesting date.
(2) Shares vest in equal monthly installments over four years, 1/48th per month. The first shares vest one month after the date of grant.
(3) Shares vest in equal monthly installments over three years, 1/36th per month. The first shares vest one month after the date of grant.
(4) Shares vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the
following two years.
(5) Shares vest 100% on the first anniversary of the date of grant.
(6) These are cash-settled stock appreciation rights that vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24
equal monthly installments over the following two years. Each of the executives also received cash-settled performance stock units on July 9, 2020, with
vesting contingent upon the successful result of our Phase 3 clinical trial. The trial concluded in August 2020 and did not achieve its primary endpoints.
The performance stock units will not vest and none were outstanding at December 31, 2020.
Potential Payments Upon Termination of Employment or Change in Control
As discussed under the caption "—Employment Agreements" above, we have agreements with our named executive officers pursuant to which they
will receive severance payments upon certain termination events. The information below describes certain compensation that would be available under our
existing plans and arrangements if (i) the named executive officer was terminated as of December 31, 2020 or (ii) if a Change in Control, as defined in the
applicable employment agreement or plan, occurred on December 31, 2020 and the named executive officer's employment had been subsequently
terminated on the same date.
Acceleration of Equity Awards in connection with a Change in Control
Pursuant to the terms of each named executive officer's option agreements reflecting options granted under the 2013 Plan, in the event of a "Change in
Control" that occurs during any time prior to such named executive officer's Termination of Service (as such terms are defined in our 2013 Plan) with us,
all stock options granted pursuant to such option agreement shall fully vest and become exercisable. Pursuant to the terms of each named executive officer's
option agreements reflecting options granted under the 2018 Plan, in the event of a "Change in Control" in which the Company is not the surviving
corporation (or survives only as a subsidiary of another corporation) and the options are assumed by, or replaced with awards with comparable terms by, the
surviving corporation (or parent or subsidiary of the surviving corporation) and the named executive officer's employment or service is terminated without
"Cause" or the named executive officer terminates his employment for "Good Reason" (as such terms are defined in the applicable option grant agreement),
all such stock options granted pursuant to such option agreement shall fully vest and become exercisable upon termination of employment or service. In the
event that the surviving corporation (or a parent or subsidiary of the surviving corporation) does not assume or replace the options with grants that have
comparable terms, and named executive officer is employed by, or providing services to, the Company and its subsidiaries on the date of the Change in
Control, all stock options granted pursuant to such option agreement shall fully vest and become exercisable.
Termination Other than for Cause, Death or Disability; Resignation for Good Reason
The payments and benefits to which each named executive officer would be entitled in the event the named executive officer's employment is
terminated for any reason other than for cause, death, or disability, or if the named executive officer resigns for good reason, whether or not following a
"change in control" is described under the caption "—Employment Agreements" above.
11
Director Compensation
The following table summarizes compensation paid to our non-employee directors in fiscal 2020.
Name
Jerome E. Groopman, M.D.
Michael B. Hoffman(2)
James J. Marino
Viren Mehta
E. Premkumar Reddy, Ph.D.(3)
M. Teresa Shoemaker
Jack E. Stover
Fees Earned or
Paid in Cash ($)
Stock Option
Awards ($) (1)
All Other
Compensation ($)
Total ($)
61,500
52,667
84,167
77,000
44,167
46,083
85,000
6,460
6,460
6,460
6,460
6,460
6,460
6,460
—
—
—
—
66,000(4)
—
—
67,960
59,127
90,627
83,460
116,627
52,543
91,460
(1) The amounts shown represent the aggregate grant date fair value related to the grant of 125,000 cash-settled stock appreciation rights to each of our
non-employee directors on July 9, 2020, calculated in accordance with FASB ASC Topic 718. These stock appreciation rights vest on the first
anniversary of the grant and expire ten years after the grant date and are subject to the director’s continued service. Additional information concerning
our financial reporting of stock appreciation rights is presented in Note 10 to our Consolidated Financial Statements set forth in our Annual Report on
Form 10-K for the year ended December 31, 2020.
(2) Mr. Hoffman resigned from our Board of Directors on August 27, 2020.
(3) Dr. Reddy resigned from our Board of Directors on August 27, 2020.
(4) Represents consulting fees paid to Dr. Reddy. See "Certain Relationships and Related Person Transactions."
(5) At December 31, 2020, the aggregate number of outstanding stock option awards held by each non-employee director was: Dr. Groopman—12,350;
Mr. Marino—12,032; Dr. Mehta—12,030; Ms. Shoemaker—0; and Mr. Stover—11,965. At December 31, 2020, the aggregate number of stock
appreciation rights held by each non-employee director was: Dr. Groopman—125,000; Mr. Marino—125,000; Dr. Mehta—125,000; Ms. Shoemaker
—125,000; and Mr. Stover—125,000.
In June 2013, our Board of Directors approved a non-employee director compensation policy, which became effective for all non-employee directors in
July 2013. In June 2018, the Board of Directors revised the policy to change the retainer amounts and the number of options members of our Board of
Directors would receive, based on a benchmarking study comparing our director compensation to a group of comparable peer companies. In accordance
with this policy, each non-employee director receives an annual base retainer of $40,000. In addition, our non-employee directors receive the following
cash compensation for board services, as applicable:
• the chairman of our Board of Directors receives an additional annual retainer of $40,000;
• each member of our audit, compensation and nominating and corporate governance committees receives an additional retainer of $7,500, $5,000
and $4,000, respectively; and
• each chairperson of our audit, compensation and nominating and corporate governance committees receives an additional annual retainer of
$15,000, $10,000 and $8,000, respectively, in addition to the retainer received for service as a member of such committee.
All amounts are paid in quarterly installments.
In addition, in accordance with the existing policy, newly appointed non-employee directors receive a one-time initial award of options to purchase
11,666 shares of our common stock, which vests annually over a three-year period subject to the director's continued service on the Board of Directors.
Thereafter, each non-employee director receives an annual award of options to purchase 5,833 shares of our common stock, which vests on the first
anniversary of the grant, subject to the director's continued service on the Board of Directors.
All of our directors are eligible to receive additional discretionary awards under our 2018 Omnibus Incentive Compensation Plan, as previously
amended (the “2018 Plan”), subject to the annual limit set forth in the 2018 Plan.
We reimburse each non-employee director for out-of-pocket expenses incurred in connection with attending our Board of Directors and committee
meetings. Compensation for our directors, including cash and equity compensation, is determined, and remains subject to adjustment, by our Board of
Directors.
12
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
Equity Compensation Plan Information
The following table summarizes the total number of outstanding options and shares available for other future issuances of options under all of our
equity compensation plans as of December 31, 2020. All of the outstanding awards listed below were granted under our 2013 Equity Compensation Plan
and 2018 Plan. See "Stock Option and Other Compensation Plans" above for a summary of the 2018 Plan.
Plan Category
Equity compensation plans approved by stockholders
Equity compensation plans not approved by stockholders
Number of Shares to
be Issued Upon
Exercise of
Outstanding
Options,
Warrants and
Rights
Weighted-Average
Exercise Price of
Outstanding
Options,
Warrants and
Rights
Number of Shares
Remaining
Available
for Future Issuance
Under the Equity
Compensation Plan
(Excluding Shares
in
First Column)
869,095 $
—
24.58
—
185,089
—
PRINCIPAL STOCKHOLDERS
The following table sets forth certain information regarding the beneficial ownership of common stock as of March 31, 2021 by (a) each person
known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock, (b) each of our named executive officers
identified on page 7 of this Amendment under the heading, “2020 Summary Compensation Table,”, (c) each of our directors, and (d) all of our executive
officers and directors as a group.
The percentage of common stock outstanding is based on 236,612,391 shares of common stock outstanding on March 31, 2021. For purposes of
the table below, and in accordance with the rules of the SEC, we deem shares of common stock subject to warrants and options that are currently
exercisable or exercisable within sixty days of March 31, 2021 to be outstanding and to be beneficially owned by the person holding the warrants and
options for the purpose of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the
percentage ownership of any other person. Except as otherwise noted, each of the persons or entities in this table has sole voting and investing power with
respect to all of the shares of common stock beneficially owned by him, her or it, subject to community property laws, where applicable. Except as
otherwise noted below, the street address of each beneficial owner is c/o Onconova Therapeutics, Inc., 375 Pheasant Run, Newtown, PA 18940.
Name and Address of Beneficial Owner
5% or greater stockholders:
Lincoln Park Capital Fund, LLC, Lincoln Park Capital, LLC, Rockledge Capital Corporation, Joshua B.
Scheinfeld, Alex Noah Investors, Inc., Jonathan I. Cope
440 North Wells, Suite 410
Chicago, Illinois 60654 (1)
Directors, Director Nominees and Named Executive Officers:
Jerome E. Groopman, M.D.(2)
Manoj Maniar, Ph.D.(3)
James J. Marino(4)
Steven M. Fruchtman, M.D.(5)
Viren Mehta(6)
Jack E. Stover(7)
M. Teresa Shoemaker
Richard C. Woodman, M.D.(8)
Mark Guerin(9)
All current executive officers, directors and director nominees as a group (7 persons) (10)
*Represents a beneficial ownership of less than one percent of our outstanding common stock.
Number of
Shares
Beneficially
Owned
Percentage of
Shares
Beneficially
Owned
13,639,411
5.8%
22,336
4
392,748
513,767
512,985
15,106
50,735
37,473
293,456
2,068,533
*
*
*
*
*
*
*
*
0.9%
(1) Based solely on a Schedule 13G filed with the SEC on January 8, 2021. The Schedule 13G was filed by Lincoln Park Capital Fund, LLC, Lincoln
Park Capital, LLC, Rockledge Capital Corporation, Joshua B. Scheinfeld, Alex Noah Investors, Inc. and Jonathan I. Cope. According to the Schedule
13G, as of January 7, 2021, Lincoln Park Capital Fund, LLC, Lincoln Park Capital, LLC, Rockledge Capital Corporation, Joshua B. Scheinfeld, Alex
Noah Investors, Inc. and Jonathan I. Cope have shared voting power and shared dispositive power with regard to 13,639,411 of common stock,
representing approximately 6.52% of the common stock.
13
(2) Includes 12,335 shares of common stock issuable upon the exercise of options that are currently exercisable or exercisable within sixty days of the
record date.
(3) Manoj Maniar, Ph.D. was terminated as Senior Vice President, Product Development of the Company on December 15, 2020.
(4) Includes 162,032 shares of common stock issuable upon the exercise of warrants and options that are currently exercisable or exercisable within
sixty days of the record date.
(5) Includes 258,643 shares of common stock issuable upon the exercise of warrants and options that are currently exercisable or exercisable within
sixty days of the record date.
(6) Includes (i) 54 shares of common stock held by Mehta Partners, LLC, (ii) 56 shares of common stock held by Viram Foundation and (iii) 262,030
shares of common stock issuable upon the exercise of warrants and options that are currently exercisable or exercisable within sixty days of the record
date. Dr. Mehta, as managing member, has voting and dispositive power with regard to the shares held by Mehta Partners, LLC. Dr. Mehta, as trustee
has voting and dispositive power with regard to the shares held by Viram Foundation.
(7) Includes 11,965 shares of common stock issuable upon the exercise of options that are currently exercisable or exercisable within sixty days of the
record date.
(8) Includes 37,473 shares of common stock issuable upon the exercise of options that are currently exercisable or exercisable within sixty days of the
record date. Richard C. Woodman, M.D. resigned as Senior Vice President, Research and Development and Chief Medical Officer of the Company on
January 15, 2021.
(9) Includes 148,243 shares of common stock issuable upon the exercise of warrants and options that are currently exercisable or exercisable within
sixty days of the record date.
(10) Includes 989,546 shares of common stock issuable upon the exercise of warrants and options that are currently exercisable or exercisable within
sixty days of the record date.
14
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
Review and Approval of Related Person Transactions
The audit committee of our Board of Directors is charged with the responsibility of reviewing and approving all related person transactions (as defined
in SEC regulations), and periodically reassessing any related person transaction that we enter to ensure continued appropriateness. This responsibility is set
forth in our audit committee charter. A related party transaction will only be approved if the audit committee determines that the transaction is in the best
interests of the Company. If a director is involved in the transaction, he or she will recuse himself or herself from all decisions regarding the transaction.
The following is a description of transactions during fiscal 2020, to which we have been a party, in which the amount involved in the transaction
exceeds the lesser of $120,000 or 1% of total assets, and in which any of our current directors, executive officers or to our knowledge, beneficial owners of
more than 5% of our capital stock or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest, other than the
employment relationships with our executive officers and the related compensation solely resulting from those employment relationships.
On May 3, 2010, as subsequently amended, we entered into a research agreement with the Mount Sinai School of Medicine ("Mount Sinai"), with
which E. Premkumar Reddy, Ph.D., a former member of our Board of Directors, is associated. The agreement expired in June 2020 and was not renewed.
The board member left the Company’s board in August 2020. The research was undertaken by Mount Sinai on our behalf. Mount Sinai, in connection with
us, will prepare applications for patents generated from the research. Results from all projects will belong exclusively to Mount Sinai, but we will have an
exclusive option to license any inventions. Payments to Mount Sinai for the year ended December 31, 2020 were $201,000.
See “Item 10. Directors, Executive Officers and Corporate Governance; Corporate Governance, Board Composition” above for a discussion regarding
the independence of the members of our Board of Directors.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.
Fees of Independent Registered Public Accounting Firm
The following table summarizes the fees of Ernst & Young LLP, our independent registered public accounting firm, billed to us for each of the last
two fiscal years.
Fee Category
Audit Fees(1)
Audit-Related Fees(2)
Tax Fees(3)
Total Fees
Fiscal 2020
Fiscal 2019
$
$
297,500 $
—
—
297,500 $
359,000
—
—
359,000
(1)
(2)
Audit fees consist of fees for the audits of fiscal 2020 and 2019 and quarterly reviews of our consolidated financial statements and other
professional services provided in connection with statutory and regulatory filings or engagements.
Audit-related fees consist of fees for assurance and related services that are reasonably related to the performance of the audit and the review of
our consolidated financial statements and which are not reported under "Audit Fees."
(3)
Tax fees for fiscal 2020 and fiscal 2019 include fees for tax advice, tax return preparation assistance and review.
Pre-Approval Policies and Procedures
Our audit committee's policy is that all audit services and all non-audit services to be provided to us by our independent registered public accounting
firm must be approved in advance by the audit committee. The audit committee's approval procedures include the review and approval of engagement
letters from our independent registered public accounting firm that document the fees for all audit services and non-audit services, primarily tax advice and
tax return preparation and review.
All audit services and all non-audit services in fiscal 2020 were pre-approved by our audit committee. Our audit committee has determined that the
provision of the non-audit services for which these fees were rendered is compatible with maintaining the independent auditor's independence.
15
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
PART IV
Financial Statements
Included in Part II, Item 8 of the Original Report.
Exhibits
See Exhibit Index.
16
EXHIBITS INDEX
Exhibit
Number
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
4.1
4.2
4.3
4.4
4.5
Exhibit Description
Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the
Company’s Current Report on Form 8-K filed on July 25, 2013).
Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc. (Incorporated by
reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 31, 2016).
Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc., as amended
(Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 22, 2018).
Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc., as amended
(Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 8, 2018).
Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of Onconova Therapeutics, Inc., as amended
(Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on September 25, 2018).
Certificate of Designation of Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 to the Company’s Current
Report on Form 8-K filed on February 8, 2018).
Certificate of Designation of Series B Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 to the Company’s Current
Report on Form 8-K filed on April 30, 2018).
Amended and Restated Bylaws of Onconova Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Current
Report on Form 8-K filed on July 25, 2013).
Form of Certificate of Common Stock (Incorporated by reference to Exhibit 4.1 to Pre-Effective Amendment No. 1 the Company’s
Registration Statement on Form S-1 filed on July 11, 2013).
Eighth Amended and Restated Stockholders’ Agreement, effective as of July 27, 2012, by and among Onconova Therapeutics, Inc. and
certain stockholders named therein (Incorporated by reference to Exhibit 4.2 to Pre-Effective Amendment No. 1 to the Company’s
Registration Statement on Form S-1 filed on July 11, 2013).
Amendment No. 1 to Eighth Amended and Restated Stockholders’ Agreement, effective as of July 9, 2013 (Incorporated by reference to
Exhibit 4.2 to Pre-Effective Amendment No. 1 the Company’s Registration Statement on Form S-1 filed on July 11, 2013).
Form of Warrant Certificate, issued pursuant to Warrant Agreement, dated as of July 27, 2016, by and between Onconova
Therapeutics, Inc. and Wells Fargo Bank, N.A., as Warrant Agent (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly
Report on Form 10-Q filed on August 15, 2016).
Warrant Agreement, dated as of July 27, 2016, by and between Onconova Therapeutics, Inc. and Wells Fargo Bank, N.A., as Warrant
Agent (Incorporated by reference to Exhibit 4.2 to the Company’s Quarterly Report on Form 10-Q filed on August 15, 2016).
17
Exhibit
Number
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
4.14
4.15
4.16
4.17
4.18
4.19
4.20
4.21
4.21
4.22
Exhibit Description
Form of Pre-Funded Warrants, issued as of July 27, 2016 (Incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on
Form 10-Q filed on August 15, 2016).
Form of Underwriter Warrant, issued as of February 12, 2018 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on
Form 8-K filed on February 8, 2018).
Form of Preferred Stock Warrant, issued as of February 12, 2018 (Incorporated by reference to Exhibit 4.2 to the Company’s Current
Report on Form 8-K filed on February 8, 2018).
Form of Pre-Funded Warrant, issued as of February 12, 2018 (Incorporated by reference to Exhibit 4.3 to the Company’s Current Report on
Form 8-K filed on February 8, 2018).
Form of Preferred Stock Warrant, issued as of May 1, 2018 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on
Form 8-K filed on April 30, 2018).
Form of Pre-Funded Warrant, issued as of May 1, 2018 (Incorporated by reference to Exhibit 4.2 to the Company’s Current Report on
Form 8-K filed on April 30, 2018).
First Amendment to Underwriter Series A Convertible Preferred Stock Purchase Warrant, dated as of September 24, 2018 (Incorporated by
reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2018).
Form of Placement Agent Common Stock Purchase Warrant, issued as of September 25, 2019 (Incorporated by reference to Exhibit 4.1 to
the Company’s Current Report on Form 8-K filed on September 25, 2019).
Form of Letter Amendment to Warrants, dated as of September 23, 2019 (Incorporated by reference to Exhibit 4.1 to the Company’s
Quarterly Report on Form 10-Q filed on November 12, 2019).
Form of Common Stock Purchase Warrant, issued as of November 25, 2019 (Incorporated by reference to Exhibit 4.1 to the Company’s
Current Report on Form 8-K filed on November 26, 2019).
Form of Pre-Funded Common Stock Warrant, issued as of November 25, 2019 (Incorporated by reference to Exhibit 4.2 to the Company’s
Current Report on Form 8-K filed on November 26, 2019).
Form of Placement Agent Common Stock Purchase Warrant, issued as of November 25, 2019 (Incorporated by reference to Exhibit 4.3 to
the Company’s Current Report on Form 8-K filed on November 26, 2019).
Form of Common Stock Purchase Warrant, issued as of December 10, 2019 (Incorporated by reference to Exhibit 4.1 of the Company’s
Current Report on Form 8-K filed on December 10, 2019).
Form of Placement Agent Common Stock Purchase Warrant, issued as of December 10, 2019 (Incorporated by reference to Exhibit 4.2 of
the Company’s Current Report on Form 8-K filed on December 10, 2019).
Form of Common Stock Purchase Warrant, issued as of December 2019 (Incorporated by reference to Exhibit 4.1 to the Company’s Current
Report on Form 8-K filed on December 19, 2019).
Form of Placement Agent Common Stock Purchase Warrant, issued as of December 19, 2019 (Incorporated by reference to Exhibit 4.1 to
the Company’s Current Report on Form 8-K filed on December 19, 2019).
Form of Placement Agent Common Stock Purchase Warrant, issued as of January 3, 2020 (Incorporated by reference to Exhibit 4.1 to the
Company’s Current Report on Form 8-K filed on January 3, 2020).
Description of the Company’s Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended (Incorporated by
reference to Exhibit 4.22 to the Company’s Annual Report on Form 10-K filed on March 27, 2020).
18
Exhibit
Number
10.1*
10.2*
10.3*
10.4*
10.5*
10.6+
10.7+
10.8+
10.9+
10.10+
10.11+
10.12+
10.13*
10.14
Exhibit Description
License Agreement, effective as of July 5, 2011, by and between Onconova Therapeutics, Inc. and SymBio Pharmaceuticals Limited
(Incorporated by reference to Exhibit 10.2 to Pre-Effective Amendment No. 2 the Company’s Registration Statement on Form S-1 filed on
July 18, 2013).
First Amendment to License Agreement, effective as of September 2, 2011, by and between Onconova Therapeutics, Inc. and SymBio
Pharmaceuticals Limited (Incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1 filed on June 14,
2013).
License Agreement, effective as of January 1, 1999, by and between Onconova Therapeutics, Inc. and Temple University — Of The
Commonwealth System of Higher Education (Incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on
Form S-1 filed on June 14, 2013).
Amendment to License Agreement, effective as of September 1, 2000, by and between Temple University — Of The Commonwealth
System of Higher Education and Onconova Therapeutics, Inc. (Incorporated by reference to Exhibit 10.5 to the Company’s Registration
Statement on Form S-1 filed on June 14, 2013).
Amendment #1 to Exclusive License Agreement, effective as of March 21, 2013, by and between Temple University — Of The
Commonwealth System of Higher Education and Onconova Therapeutics, Inc. (Incorporated by reference to Exhibit 10.6 to the
Company’s Registration Statement on Form S-1 filed on June 14, 2013).
Onconova Therapeutics, Inc. 2007 Equity Compensation Plan, and forms of agreement thereunder (Incorporated by reference to
Exhibit 10.13 to Pre-Effective Amendment No. 1 the Company’s Registration Statement on Form S-1 filed on July 11, 2013).
Consulting Agreement, effective as of January 1, 2012, by and between Onconova Therapeutics, Inc. and E. Premkumar Reddy, Ph.D.,
including Consultant Agreement Renewal, dated February 27, 2013 (Incorporated by reference to Exhibit 10.23 to the Company’s
Registration Statement on Form S-1 filed on June 14, 2013).
Form of Indemnification Agreement entered into by and between Onconova Therapeutics, Inc. and each director and executive officer
(Incorporated by reference to Exhibit 10.24 to Pre- Effective Amendment No. 1 the Company’s Registration Statement on Form S-1 filed on
July 11, 2013).
Onconova Therapeutics, Inc. 2013 Equity Compensation Plan, and forms of agreement thereunder (Incorporated by reference to
Exhibit 10.25 to Pre-Effective Amendment No. 1 the Company’s Registration Statement on Form S-1 filed on July 11, 2013).
Onconova Therapeutics, Inc. 2013 Performance Bonus Plan (Incorporated by reference to Exhibit 10.26 to Pre-Effective Amendment No. 1
the Company’s Registration Statement on Form S-1 filed on July 11, 2013).
Employment Agreement, effective as of July 1, 2015, by and between Onconova Therapeutics, Inc. and Mark Guerin (Incorporated by
reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on February 17, 2016).
Amended and Restated Employment Agreement, effective as of July 1, 2015, by and between Onconova Therapeutics, Inc. and Steven M.
Fruchtman, M.D. (Incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed on August 13, 2015).
License, Development and Commercialization Agreement, dated as of March 2, 2018, by and between Onconova Therapeutics, Inc. and
Pint International SA (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on May 15, 2018).
Securities Purchase Agreement, dated as of March 2, 2018, by and between Onconova Therapeutics, Inc. and Pint Pharma GmbH
(Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on May 15, 2018).
19
Exhibit
Number
10.15.1+
10.15.2+
10.16+
10.17+
10.18+
10.19
10.20
10.21
10.22
10.23**
10.24
10.25
10.26**
10.27
Exhibit Description
Amended and Restated Employment Agreement, effective as of June 19, 2018, by and between Onconova Therapeutics, Inc. and Steven
M. Fruchtman, M.D. (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 14,
2018).
Amendment to Employment Agreement, dated as of March 18, 2021, by and between Onconova Therapeutics, Inc. and Steven M.
Fruchtman, M.D.
Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan, as approved by the stockholders (Incorporated by reference to
Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 29, 2018).
Form of Nonqualified Stock Option Award Agreement under the Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation
Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 30, 2018).
Employment Agreement, effective as of November 5, 2018, by and between Onconova Therapeutics, Inc. and Richard C. Woodman,
M.D. (Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q filed on November 14, 2018).
License and Collaboration Agreement, effective as of May 10, 2019, by and between Onconova Therapeutics, Inc. and HanX
Biopharmaceuticals, Inc. (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 14,
2019).
Securities Purchase Agreement, effective as of May 10, 2019, by and between Onconova Therapeutics, Inc. and HanX
Biopharmaceuticals, Inc. (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 14,
2019).
Securities Purchase Agreement, effective as of May 10, 2019, by and between Onconova Therapeutics, Inc. and Abundant New
Investments Ltd. (Incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on August 14, 2019).
Form of Securities Purchase Agreement, effective as of September 23, 2019, by and between Onconova Therapeutics, Inc. and each
purchase identified on the signature pages thereto (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on
Form 8-K filed on September 25, 2019).
Distribution, License and Supply Agreement, effective as of November 20, 2019, by and between Onconova Therapeutics, Inc. and
Knight Therapeutics, Inc. (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on
November 21, 2019).
Form of Securities Purchase Agreement, effective as of November 21, 2019, by and between Onconova Therapeutics, Inc. and each
purchase identified on the signature pages thereto (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on
Form 8-K filed on November 26, 2019).
Form of Securities Purchase Agreement, effective as of December 6, 2019, by and between Onconova Therapeutics, Inc. and each
purchase identified on the signature pages thereto (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on
Form 8-K filed on December 10, 2019).
Distribution, License and Supply Agreement, by and between Onconova Therapeutics, Inc. and Specialised Therapeutics Asia Pte. Ltd.,
effective as of December 18, 2019 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on
December 19, 2019).
Form of Securities Purchase Agreement, by and between Onconova Therapeutics, Inc. and each purchaser identified on the signature
pages thereto, effective as of December 17, 2019 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-
K filed on December 19, 2019).
20
Exhibit
Number
10.28
10.29+
10.30+
10.31+
21.1#
23.1#
31.1
31.2
32.1#
32.2#
101.INS
101.SCH
101.CAL
101.DEF
101.LAB
101.PRE
Exhibit Description
Form of Securities Purchase Agreement, by and between Onconova Therapeutics, Inc. and each purchaser identified on the signature
pages thereto, effective as of December 31, 2019 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-
K filed on January 3, 2020).
Form of Stock Appreciation Right Award Agreement (for Employees) (Incorporated by reference to Exhibit 10.1 to the Company’s
Current Report on Form 8-K filed on July 10, 2020).
Form of Stock Appreciation Right Award Agreement (for Non-Employee Directors) (Incorporated by reference to Exhibit 10.2 to the
Company’s Quarterly Report on Form 10-Q filed on November 16, 2020).
Form of Performance Stock Unit Award Agreement (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on
Form 8-K filed on July 10, 2020).
Subsidiaries of Onconova Therapeutics, Inc.
Consent of Ernst & Young, LLP.
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.
Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.
XBRL Instance
XBRL Taxonomy Extension Schema Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Labels Linkbase Document
XBRL Taxonomy Extension Presentation Linkbase Document
+
Indicates management contract or compensatory plan.
* Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the
Securities and Exchange Commission.
** Portions of the exhibit have been omitted.
#
Previously filed.
21
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
SIGNATURES
its behalf by the undersigned, thereunto duly authorized.
Date: April 30, 2021
Onconova Therapeutics, Inc.
By: /s/ STEVEN M. FRUCHTMAN, M.D.
Steven M. Fruchtman
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated:
Signature
Title
/s/ STEVEN M. FRUCHTMAN, M.D.
Steven M. Fruchtman, M.D.
Director, President and Chief Executive Officer
(Principal Executive Officer)
/s/ MARK GUERIN
Mark Guerin
/s/ JAMES J. MARINO
James J. Marino
/s/ JEROME E. GROOPMAN, M.D.
Jerome E. Groopman, M.D.
/s/ VIREN MEHTA, PH.D.
J Viren Mehta, Ph.D.
/s/ MARY TERESA SHOEMAKER
Mary Teresa Shoemaker
/s/ JACK E. STOVER
Jack E. Stover
Chief Financial Officer (Principal Financial
Officer and Principal Accounting Officer)
Chairman, Board of Directors
Director
Director
Director
Director
22
Date
April 30, 2021
April 30, 2021
April 30, 2021
April 30, 2021
April 30, 2021
April 30, 2021
April 30, 2021
I, Steven M. Fruchtman, certify that:
1. I have reviewed this Annual Report on Form 10-K/A of Onconova Therapeutics, Inc.; and
CERTIFICATIONS
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report.
Exhibit 31.1
Dated: April 30, 2021
/s/ STEVEN M. FRUCHTMAN, M.D.
Steven M. Fruchtman M.D.
President and Chief Executive Officer
(Principal Executive Officer and Principal Operating Officer)
I, Mark Guerin, certify that:
1. I have reviewed this Annual Report on Form 10-K/A of Onconova Therapeutics, Inc.; and
CERTIFICATIONS
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report.
Exhibit 31.2
Dated: April 30, 2021
/s/ MARK GUERIN
Mark Guerin
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)